alexa Regulatory Effect Of β-sitosterolonatopic Dermatitis-like Skin Lesions | 23161
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Translational Medicine
November 03-05, 2014 Las Vegas, USA

Hyun-JaJeong
Posters: Transl Med
DOI: 10.4172/2161-1025.S1.013
Abstract
β-sitosterol (BS) is one of the most common forms of phytosterols and has anti-cancer, anti-oxidant, anti-bacterial,and anti-inflammatory effects. However, the effect of BS on atopic dermatitis (AD) has not been elucidated. In the present study, weinvestigated whether BS would be an effective treatment against AD. We treated BS on 2,4-dinitrofluorobenzene (DNFB)-inducedAD-like skin lesions in NC/Nga mice and anti-CD3/anti-CD28-stimulated splenocytes. BS decreased the clinical symptoms in DNFB-treated NC/Nga mice. Infiltration of eosinophils, mast cells, CD4+ T cells, and macrophages and number of scratching were clearly decreased in the BS-treated group compared with the DNFB-treated group. BS significantlydecreased the protein and mRNA levels of inflammation-related genes in the AD skin lesions. BS significantly decreased the levels ofinterleukin-4,IgE, and histamine in the serum of DNFB-treated NC/Nga mice. The activation of mast cell-derived caspase-1was reduced by treatment with BS in the AD skin lesions. BS also significantly decreased the production of inflammatory cytokine from the stimulated splenocytes. These results provide additional evidence thatBS may be considered an effective therapeutic drug for the treatment of AD.
Biography
Hyun-JaJeong has completed Postdoctoral studies with a major in Molecular Biology from Chonbuk National University. She has published more than 200 papers in reputed journals and serving as a Deputy Editor of international journal, TANG (Humanitas Medicine).
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version